Abstract B033: Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-b033
Abstract: Single-agent targeting of RAS-mutated cancers using RAF/MEK/ERK or PI3K/AKT pathway inhibitors is ineffective; blocking one pathway relieves negative feedback control of RTK signaling and hyperactivates parallel effector pathways. While combined MEK and PI3K inhibition is… read more here.
Keywords: mutated cancers; ras signaling; signaling essential; mutant ras ... See more keywords